CMAB Biopharma Inc. (CMAB), is a full-service contract development and manufacturing organization (CDMO) established in June 2017, which is dedicated to providing process development and manufacturing services for biologic products. We are a flexible full-service CDMO dedicated to providing bespoke development manufacturing services of antibodies and biologics for clients in China and across the globe. Our adaptable, service-oriented business enables clients to take their innovative concepts for tomorrow's medicines from DNA to clinical product today.
Strong commercial backing and committed investors have supported the development of CMAB's Pilot Facility in Suzhou, China. The Facility is designed to provide full-service manufacturing of Drug Substance and Drug Product, including Process and Analytical Development for pre-clinical and clinical stage biologics manufacturing.
CMAB have the vision to be the leading CDMO in China and plan rapid expansion to provide a global footprint and compelling commercial production capability.
CMAB aims to provide the most advanced technologies and highest quality services, and we are strongly committed to protecting our clients' IP interests.
At CMAB, we employ a strict “pure-play CDMO” business model, focused solely on manufacturing for our clients and not developing or partnering on our own biologics. This is to ensure the protection of our client’s intellectual property and to avoid any potential conflicting interests. We also invested over 20 million RMB in adopting leading information technology products to streamline operations and assure delivery from our inception.
CMAB has embraced a culture of vigilance in best practice security standards, covering ALL aspects of the robust IP protection system, including comprehensive data networks, storage and back-up systems, controlled office system and latency issues, to maintain data confidentiality, integrity and availability, so our clients can feel confident and reassured their intelligent property is actively being protected.